Trial Profile
Phase 1B Study of PTC299 in Relapsed/Refractory Acute Leukemias
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 08 Feb 2022
Price :
$35
*
At a glance
- Drugs Emvododstat (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors PTC Therapeutics
- 18 Jan 2022 Status changed from recruiting to discontinued because sponsor terminated the study.
- 12 Oct 2021 Planned End Date changed from 30 Jun 2021 to 31 May 2022.
- 12 Oct 2021 Planned primary completion date changed from 31 May 2021 to 30 Apr 2022.